Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump

Hepatology

Volumn 60, Issue 3, 2014, Pages 1015-1022

  Aleo, Michael D ^a   Luo, Yi ^a   Swiss, Rachel ^a   Bonin, Paul D ^a   Potter, David M ^a   Will, Yvonne ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BILE ACID; BILE SALT; BILE SALT EXPORT PUMP; BILE SALT EXPORT PUMP INHIBITOR; BUSPIRONE; FUROSEMIDE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG CYTOTOXICITY; DRUG DISTRIBUTION; DRUG EXPOSURE; DRUG POTENCY; DRUG SAFETY; IC 50; LIVER CELL; LIVER INJURY; LIVER MITOCHONDRION; MALE; MAXIMUM PLASMA CONCENTRATION; METABOLITE; MITOCHONDRIAL RESPIRATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TRANSPORT; RAT; RISK FACTOR; TOXIC HEPATITIS;

ANIMALS; ATP-BINDING CASSETTE TRANSPORTERS; DRUG-INDUCED LIVER INJURY; HUMANS; MALE; MITOCHONDRIA, LIVER; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX;

EID: 84906937883     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27206     Document Type: Article

References (50)

1. Bell LN, Chalasani N. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis 2009;29:337-347.
2. Russo MW, Galanko JA, Shrestha R, Fried MW, Watkins P. Liver transplantation for acute liver failure from drug induced liver injury in the United States. Liver Transpl 2004;10:1018-1023.
3. Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246-2259.
4. Ostapowicz G, Fontana RJ, Schiodt FV, Larson A, Davern TJ, Han SH, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947-954.
5. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, et al. Concordance of the toxicity of pharmaceuticals in humans and in animals. Regul Toxicol Pharmacol 2000;32:56-67.
6. Tamaki C, Nagayama T, Hashiba M, Fujiyoshi M, Hizue M, Kodaira H, et al. Potentials and limitations of nonclinical safety assessment for predicting clinical adverse drug reactions: correlation analysis of 142 approved drugs in Japan. J Toxicol Sci 2013;38:581-598.
7. Senior JR. What is idiosyncratic hepatotoxicity? What is it not? Hepatology 2008;47:1813-1815.
8. Ulrich RG. Idiosyncratic toxicity: a convergence of risk factors. Annu Rev Med 2007;58:17-34.
9. Pachkoria K, Lucena MI, Molokhia M, Cueto R, Carballo AS, Carvajal A, et al. Genetic and molecular factors in drug-induced liver injury: a review. Curr Drug Saf 2007;2:97-112.
10. Wilke RA, Lin DW, Roden DM, Watkins PB, Flockhart D, Zineh I, et al. Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges. Nat Rev Drug Discov 2007;6:904-916.
11. Russmann S, Jetter A, Kullak-Ublick GA. Pharmacogenetics of drug-induced liver injury. Hepatology 2010;52:748-761.
12. Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013;58:388-396.
13. Park BK, Boobis A, Clarke S, Goldring CE, Jones D, Kenna JG, et al. Managing the challenge of chemically reactive metabolites in drug development. Nat Rev Drug Discov 2011;10:292-306.
14. Obach RS, Kalgutkar AS, Soglia JR, Zhao SX. Can in vitro metabolism-dependent covalent binding data in liver microsomes distinguish hepatotoxic from nonhepatotoxic drugs? An analysis of 18 drugs with consideration of intrinsic clearance and daily dose. Chem Res Toxicol 2008;21:1814-1822.
15. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-236.
16. Alrefai WA, Gill RK. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 2007;24:1803-1823.
17. Stieger B, Meier Y, Meier PJ. The bile salt export pump. Pflugers Arch 2007;453:611-620.
18. Suchy FJ, Ananthanarayanan M. Bile salt excretory pump: biology and pathobiology. J Pediatr Gastroenterol Nutr 2006;43(Suppl 1):S10-16.
19. Cai SY, Wang L, Ballatori N, Boyer JL. Bile salt export pump is highly conserved during vertebrate evolution and its expression is inhibited by PFIC type II mutations. Am J Physiol Gastrointest Liver Physiol 2001;281:G316-322.
20. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 2001;69:223-231.
21. Bonkovsky HL, Azar R, Bird S, Szabo G, Banner B. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig Dis Sci 2002;47:1632-1637.
22. Funk C, Ponelle C, Scheuermann G, Pantze M. Cholestatic potential of troglitazone as a possible factor contributing to troglitazone-induced hepatotoxicity: in vivo and in vitro interaction at the canalicular bile salt export pump (Bsep) in the rat. Mol Pharmacol 2001;59:627-635.
23. Tazuma S. Cyclosporin A and cholestasis: Its mechanism(s) and clinical relevancy. Hepatol Res 2006;34:135-136.
24. Stieger B. Role of the bile salt export pump, BSEP, in acquired forms of cholestasis. Drug Metab Rev 2010;42:437-445.
25. Dawson S, Stahl S, Paul N, Barber J, Kenna JG. In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans. Drug Metab Dispos 2012;40:130-138.
26. Morgan RE, Trauner M, van Staden CJ, Lee PH, Ramachandran B, Eschenberg M, et al. Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci 2010;118:485-500.
27. Thompson RA, Isin EM, Li Y, Weaver R, Weidolf L, Wilson I, et al. Risk assessment and mitigation strategies for reactive metabolites in drug discovery and development. Chem Biol Interact 2011;192:65-71.
28. Kass GE. Mitochondrial involvement in drug-induced hepatic injury. Chem Biol Interact 2006;163:145-159.
29. Dykens JA, Will Y. The significance of mitochondrial toxicity testing in drug development. Drug Discov Today 2007;12:777-785.
30. Kamiike W, Nakahara M, Nakao K, Koseki M, Nishida T, Kawashima Y, et al. Correlation between cellular ATP level and bile excretion in the rat liver. Transplantation 1985;39:50-55.
31. Slater TF, Delaney VB. Liver adenosine triphosphate content and bile flow rate in the rat. Biochem J 1970;116:303-308.
32. Chijiiwa K, Mizuta A, Ueda J, Takamatsu Y, Nakamura K, Watanabe M, et al. Relation of biliary bile acid output to hepatic adenosine triphosphate level and biliary indocyanine green excretion in humans. World J Surg 2002;26:457-461.
33. Rolo AP, Oliveira PJ, Moreno AJM, Palmeira CM. Bile acids affect liver mitochondrial bioenergetics: possible relevance for cholestasis therapy. Toxicol Sci 2000;57:177-185.
34. Dutu A, Borza V, Mosora N, Motocu M, Benga G. ATP-ase activity of mitochondria isolated from needle-biopsy liver samples of diabetic subjects. Med Interne 1985;23:201-206.
35. Rabol R, Boushel R, Almdal T, Hansen CN, Ploug T, Haugaard SB, et al. Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. Diabetes Obes Metab 2010;12:806-814.
36. Pérez-Carreras M, Del Hoyo P, Martín MA, Rubio JC, Martín A, Castellano G, et al. Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis. Hepatology 2003;38:999-1007.
37. Massart J, Begriche K, Buron N, Porceddu M, Borgne-Sanchez A, Fromenty B. Drug-induced inhibition of mitochondrial fatty acid oxidation and steatosis. Curr Pathobiol Rep 2013;1:147-157.
38. Dykens JA, Jamieson JD, Marroquin LD, Nadanaciva S, Xu JJ, Dunn MC, et al. In vitro assessment of mitochondrial dysfunction and cytotoxicity of nefazodone, trazodone, and buspirone. Toxicol Sci 2008;103:335-345.
39. Kaufmann P, Torok M, Hanni A, Roberts P, Gasser R, Krahenbuhl S. Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. Hepatology 2005;41:925-935.
40. Nadanaciva S, Dykens JA, Bernal A, Capaldi RA, Will Y. Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration. Toxicol Appl Pharmacol 2007;223:277-287.
41. Chen M, Hong H, Fang H, Kelly R, Zhou G, Borlak J, et al. Quantitative structure-activity relationship models for predicting drug-induced liver injury based on FDA-approved drug labeling annotation and using a large collection of drugs. Toxicol Sci 2013;136:242-249.
42. Chen M, Vijay V, Shi Q, Liu Z, Fang H, Tong W. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov Today 2011;16:697-703.
43. Hynes J, Swiss RL, Will Y. High-throughput analysis of mitochondrial oxygen consumption. Methods Mol Biol 2012;810:59-72.
44. Will Y, Hynes J, Ogurtsov VI, Papkovsky DB. Analysis of mitochondrial function using phosphorescent oxygen-sensitive probes. Nat Protoc 2006;1:2563-2572.
45. Hynes J, Nadanaciva S, Swiss R, Carey C, Kirwan S, Will Y. A high-throughput dual parameter assay for assessing drug-induced mitochondrial dysfunction provides additional predictivity over two established mitochondrial toxicity assays. Toxicol In Vitro 2013;27:560-569.
46. Kostrubsky SE, Strom SC, Kalgutkar AS, Kulkarni S, Atherton J, Mireles R, et al. Inhibition of hepatobiliary transport as a predictive method for clinical hepatotoxicity of nefazodone. Toxicol Sci 2006;90:451-459.
47. Agresti A. Categorical data analysis. New York: John Wiley & Sons, 1990.
48. Thompson RA, Isin EM, Li Y, Weidolf L, Page K, Wilson I, et al. In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. Chem Res Toxicol 2012;25:1616-1632.
49. Pessayre D, Mansouri A, Berson A, Fromenty B. Mitochondrial involvement in drug-induced liver injury. Handb Exp Pharmacol 2010:311-365.
50. Feng B, Xu JJ, Bi YA, Mireles R, Davidson R, Duignan DB, et al. Role of hepatic transporters in the disposition and hepatotoxicity of a HER2 tyrosine kinase inhibitor CP-724, 714. Toxicol Sci 2009;108:492-500.